Jianghua Zheng

Dr. Jianghua Zheng


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Closed access
YLY-J Liu
Y-J Liu
HZH-G Zhou
H-G Zhou
LCL-H Chen
L-H Chen
DQD-C Qu
D-C Qu
CWC-J Wang
C-J Wang
JZJianghua Zheng
Jianghua Zheng

9 April 2024 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
QTQiang Tan
Qiang Tan
ZCZhilong Chen
Zhilong Chen
HWHuaping Wu
Huaping Wu
HWHaifei Wang
Haifei Wang
JCJingquan Chen
Jingquan Chen
JZJianghua Zheng
Jianghua Zheng
Purpose: The purpose of this study is to assess the efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease (PAD) after endovascular therapy (EVT). Materials and methods: We conducted a systematic review and meta-analysis of all studies reporting the outcomes of cilostazol after femoropopliteal EVT of PAD up to September 2022. Clinical outcomes of interest included primary patency, in-stent restenosis (ISR), vessel re-occlusion, freedom from target lesion revascularization (TLR), repeat revascularization, all-cause mortality, amputation, major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs), and bleeding complication. Results: A total of 4 randomized controlled trials (RCTs) and 8 observational studies containing a total of 4898 patients met the inclusion criteria and were included in this systematic review and meta-analysis. We found that the use of cilostazol was associated with higher primary patency after femoropopliteal artery EVT (odds ratio [OR]=1.67, 95% confidence interval [CI]=1.50-1.87, p<0.001, I 2 =33.2%), a lower risk of ISR (OR=0.43, 95% CI=0.29-0.63, p<0.001, I 2 =37.6%), repeat revascularization (OR=0.43, 95% CI=0.24-0.76, p<0.005, I 2 =27.4%), and vessel re-occlusion (OR=0.59, 95% CI=0.38-0.93, p<0.05, I 2 =0%). There was an increase in freedom from TLR rate (OR=2.19, 95% CI=1.58-3.05, p<0.001, I 2 =0%), as well as a reduction in the occurrence of MALEs (OR=0.50, 95% CI=0.29-0.85, p<0.05, I 2 =0%). However, there was no significant difference in amputation, MACEs, all-cause mortality, and major bleeding complications. Subgroup analysis showed that cilostazol treatment in patients with femoropopliteal drug-eluting stents (DES) implantation remained associated with higher primary patency and a lower risk of ISR. Conclusions: After EVT of femoropopliteal artery lesions, additional oral cilostazol enhances primary patency, reduces the occurrences of ISR and vessel re-occlusion, diminishes the risks associated with MALEs, lowers the need for repeat revascularization, and increases freedom from TLR rates. However, it does not impact amputation, MACEs, all-cause mortality, or major bleeding complications. These findings suggest cilostazol as a potentially safe and effective adjunct therapy in patients with femoropopliteal PAD after EVT. Clinical Impact: After undergoing endovascular therapy (EVT) for femoropopliteal artery lesions, the addition of cilostazol to antiplatelet therapy can significantly improve primary patency, reducing the incidence of in-stent restenosis, repeat revascularization, vessel re-occlusion, and major adverse limb events while increasing freedom from target lesion revascularization rate. The simultaneous use of drug-eluting stents in the femoropopliteal artery lesions, combined with cilostazol, potentially results in a synergistic anti-stenotic effect. This therapeutic approach does not appear to be associated with an increased risk of major bleeding events or all-cause mortality. These findings provide additional evidence supporting the treatment of anti-stenosis in patients with femoropopliteal artery lesions after EVT.

11 June 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KLKun Lai
Kun Lai
LLLan Luo
Lan Luo
FZFuzhao Zhang
Fuzhao Zhang
ETEugenie Sin Sing Tan
Eugenie Sin Sing Tan
AGAnand Gaurav
Anand Gaurav
CTChung Keat Tan
Chung Keat Tan
Background: Suzetrigine (Journavx; VX-548), the first selective NaV1.8 voltage-gated sodium channel inhibitor approved by the FDA on 30 January 2025, represents a novel non-opioid option for moderate-to-severe acute pain. Given its recent market entry and unique peripheral mechanism, comprehensive post-marketing safety surveillance is essential. Objective: This study aimed to identify and characterize adverse event signals associated with suzetrigine in the FDA Adverse Event Reporting System (FAERS) using advanced disproportionality and comparator-referenced empirical Bayes (EB) methods, with external triangulation against published literature and WHO VigiBase data. Methods: We analyzed FAERS reports through the first 8 months post-approval. Disproportionality metrics (ROR, PRR, IC) were supplemented by a comparator-referenced EB profiling approach that incorporated suzetrigine, acetaminophen, ibuprofen, and background “other drugs,” generating 3,000 posterior draws per preferred term (PT). Signals with EB q05 > 2 and no comparator overlap were classified as suzetrigine-unique. High-priority PTs were triangulated with Phase II/III trial data, systematic reviews, case reports, and VigiBase report counts (February 2026). Results: Of 19 prioritized PTs, 14 were suzetrigine-unique. Dominant clusters included sensory disturbances (paresthesia, burning sensation, skin burning sensation, hypoaesthesia; EB q05 11.43–31.16), musculoskeletal events (muscle spasms EB q05 31.15), and cutaneous reactions (pruritus, rash). These signals were mechanistically consistent with peripheral NaV1.8 blockade of nociceptors and pruriceptors. Literature and VigiBase data corroborated neurological/sensory and musculoskeletal signals; psychiatric signals (euphoric mood, abnormal dreams) lacked external support and were deprioritized. Conclusion: This real-world pharmacovigilance analysis identifies a distinct safety signature for suzetrigine, with neurological and sensory disturbances (e.g., paresthesia, burning sensation, skin burning sensation, hypoaesthesia) emerging as prominent signals not fully characterized in pre-approval trials, whereas musculoskeletal and cutaneous events largely align with labeled reactions. These hypothesis-generating findings highlight the need for focused post-marketing surveillance on neurological/sensory preferred terms through prospective cohort studies and Phase IV trials to quantify incidence, identify risk factors, and optimize risk-minimization strategies for this promising non-opioid analgesic.

18 February 2025 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
QTQiang Tan
Qiang Tan
JZJian Zhang
Jian Zhang
YPYanrong Peng
Yanrong Peng
RYRui Yang
Rui Yang
YZYanbin Zhu
Yanbin Zhu
JZJianghua Zheng
Jianghua Zheng
Purpose: Abdominal aortic calcification (AAC) is related to inflammation and nutritional status. The Naples prognostic score (NPS) is an innovative biological marker capable of reflecting systemic inflammation and nutritional status. This research seeks to investigate the correlation of NPS with severe abdominal aortic calcification (SAAC).Methods: The research evaluated data obtained from the National Health and Nutrition Examination Survey (NHANES) conducted between 2013 and 2014. The variables were filtered utilizing the Least Absolute Shrinkage and Selection Operator (LASSO) regression. Weighted logistic regression models were employed to examine the association of NPS with SAAC. The predictive value of NPS for the risk of SAAC was assessed utilizing the receiver operating characteristic (ROC) curve. A subgroup analysis was conducted to assess the strength and reliability of the research findings.Results: The research encompassed 2,854 participants, among whom 303 (11.87%) exhibited SAAC. The outcomes of multivariate weighted logistic regression revealed that participants with a NPS of 3–4 points was positively correlated with SAAC in comparison to the control group [odds ratio (OR) = 2.07, 95% confidence interval (95%CI): 1.17–3.67]. The area under the curve (AUC) for predicting the risk of SAAC using NPS was 0.635. The subgroup analysis results indicated that there was no significant difference noted in the association of NPS with SAAC across various population subgroups.Conclusion: A positive association of NPS with SAAC has been observed in this research. This study offers valuable insights into the prevention and diagnosis of SAAC. Future longitudinal studies are warranted to confirm causative relationships and assess the role of NPS in clinical decision-making for SAAC.

1 January 2008 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
JZJianghua Zheng
Jianghua Zheng
KCKai Chen
Kai Chen
ZCZu-Lin Chen
Zu-Lin Chen

3 January 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
XYXi Yong✉
Xi Yong✉
TKTengyao Kang
Tengyao Kang
TLTingting Li
Tingting Li
HJHuiting Jiang
Huiting Jiang
XHXuerui Hu
Xuerui Hu
QYQin Yang
Qin Yang
Purpose: Chromosome 3 loss is an independent risk factor for uveal melanoma (UM), but its exact molecular mechanisms remain unclear. This study was designed to investigate the relationship between chromosome 3 loss and molecular alterations at multiple levels to construct a prognostic model. Methods: Forty-four UM cases with chromosome 3 loss (chr3 del group) and 36 UM cases without copy number variation on chromosome 3 (chr3 wt group) were collected from the Cancer Genome Atlas (TCGA). The TCGA dataset was subjected to a univariate Cox regression analysis to identify different expressed genes, and a subsequent random forest algorithm analysis revealed significant changes in different expressed genes, which were used to develop key biomarkers for UM. Following that, the immune cell infiltration analysis and drug sensitivity analyses were carried out. The UM cell line was then utilized to investigate the potential functions of the key biomarker via cell apoptosis, proliferation, cycle assays, WB, and RT-qPCR. Results: By analyzing the 80 cases data in TCGA, the authors unveiled molecular changes relevant to loss of chromosome 3 in UM as well as their poor survival. In addition, machine learning analysis identified three hub genes (GRIN2A, ACAN, and MMP9) as potential therapeutic targets. The differentially enriched pathways between the two groups were mainly about immune-system activity, and hub genes expression was also highly correlated with immune infiltration levels. Conclusion: Chromosome 3 loss has considerable clinical significance for UM, and GRIN2A may be useful in diagnosing, treating, and prognosticating the condition.